Pfizer

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Pfizer is one of 6 biologic programs targeting mRNA Vaccine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MRNA VaccineUnknown status

MRNA VaccinePreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in MRNA Vaccine

#DrugCompanyPhaseTrials

Navmi

SSummit Therapeutics

Phase 1

1 2

Personalized Neoantigen Tumor Vaccine

RRuijin Hospital

Phase 1

1 3

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 1

1 4

Mfolforinox

AAkeso

Phase 1

1 5

Pfizer

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Moderna

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

mRNA Vaccine1 trial

Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04900467·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pfizer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pfizer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pfizer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Pfizer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

mRNA Vaccine1 trial

References

Drug Info

Quick Facts

Related News